Quanterix Co. (NASDAQ:QTRX) Shares Purchased by Portolan Capital Management LLC

Portolan Capital Management LLC raised its position in Quanterix Co. (NASDAQ:QTRX - Free Report) by 2.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,587,824 shares of the company's stock after buying an additional 67,138 shares during the quarter. Quanterix comprises about 1.8% of Portolan Capital Management LLC's holdings, making the stock its 12th largest position. Portolan Capital Management LLC owned approximately 6.72% of Quanterix worth $27,509,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in QTRX. Bank of New York Mellon Corp boosted its holdings in Quanterix by 1.8% in the 4th quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company's stock valued at $1,150,000 after purchasing an additional 1,963 shares in the last quarter. Invesco Ltd. increased its holdings in Quanterix by 16.3% in the fourth quarter. Invesco Ltd. now owns 33,654 shares of the company's stock valued at $358,000 after buying an additional 4,729 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Quanterix by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 863,503 shares of the company's stock worth $9,181,000 after acquiring an additional 4,836 shares in the last quarter. Resona Asset Management Co. Ltd. purchased a new position in Quanterix in the 4th quarter valued at approximately $55,000. Finally, American Century Companies Inc. raised its holdings in Quanterix by 9.1% during the fourth quarter. American Century Companies Inc. now owns 71,992 shares of the company's stock worth $765,000 after purchasing an additional 6,023 shares during the last quarter. Hedge funds and other institutional investors own 86.48% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Canaccord Genuity Group cut their price target on Quanterix from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th. Scotiabank reaffirmed an "outperform" rating on shares of Quanterix in a report on Tuesday, March 25th.

Quanterix Stock Performance

QTRX stock traded down $0.01 during trading on Friday, hitting $5.15. The stock had a trading volume of 804,495 shares, compared to its average volume of 541,094. The stock has a market cap of $199.76 million, a price-to-earnings ratio of -4.86 and a beta of 1.35. The company's 50 day moving average price is $6.86 and its two-hundred day moving average price is $9.82. Quanterix Co. has a 1-year low of $4.67 and a 1-year high of $19.18.

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.03). The firm had revenue of $35.16 million for the quarter, compared to analysts' expectations of $34.93 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. As a group, sell-side analysts forecast that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.